MUC5AC and colonic neoplasm: Through CRISPR/Cas9 mediated knockout and subsequent in vitro and in vivo functional analyses, they elucidated the mechanisms by which MUC5AC contributes to tumorigenesis and drug resistance.489 Chakraborty et al. discovered the therapeutic potential of targeting the NPY/Y2R pathway in colon cancer, particularly in regulating angiogenesis.